Xenon Pharmaceuticals Valuation
| XENE Stock | USD 43.15 0.70 1.65% |
At this time, the company appears to be undervalued. Xenon Pharmaceuticals maintains a prevalent Real Value of $47.6 per share. The last-minute price of the company is $43.15. Our model calculates the value of Xenon Pharmaceuticals from examining the company fundamentals such as Shares Owned By Insiders of 0.37 %, current valuation of 2.47 B, and Return On Asset of -0.19 as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Xenon Pharmaceuticals' valuation include:
Price Book 4.0566 | Enterprise Value 2.5 B | Enterprise Value Ebitda (11.81) | Price Sales 181.4446 | Enterprise Value Revenue 10.9 K |
Undervalued
Today
Please note that Xenon Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Xenon Pharmaceuticals is based on 3 months time horizon. Increasing Xenon Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Xenon stock is determined by what a typical buyer is willing to pay for full or partial control of Xenon Pharmaceuticals. Since Xenon Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Xenon Stock. However, Xenon Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 43.15 | Real 47.6 | Target 52.69 | Hype 43.1 |
The real value of Xenon Stock, also known as its intrinsic value, is the underlying worth of Xenon Pharmaceuticals Company, which is reflected in its stock price. It is based on Xenon Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Xenon Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Xenon Pharmaceuticals helps investors to forecast how Xenon stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Xenon Pharmaceuticals more accurately as focusing exclusively on Xenon Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Xenon Pharmaceuticals' intrinsic value based on its ongoing forecasts of Xenon Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Xenon Pharmaceuticals' closest peers. If more than one evaluation category is relevant for Xenon Pharmaceuticals we suggest using both methods to arrive at a better estimate.
Xenon Pharmaceuticals Cash |
|
Xenon Valuation Trend
Comparing Xenon Pharmaceuticals' enterprise value against its market capitalization is a good way to estimate the value of Xenon Pharmaceuticals uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Xenon Pharmaceuticals Total Value Analysis
Xenon Pharmaceuticals is at this time estimated to have valuation of 2.47 B with market capitalization of 3.29 B, debt of 10.9 M, and cash on hands of 788.24 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Xenon Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.47 B | 3.29 B | 10.9 M | 788.24 M |
Xenon Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Xenon is to check how much profit was generated for every dollar of assets it reports. Xenon Pharmaceuticals maintains a negative usage of resources of -0.19 (%), losing $0.001892 for each dollar of resources held by the company. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it maintains. Specifically, asset utilization of Xenon Pharmaceuticals shows how discouraging it operates for each dollar spent on its resources.Xenon Pharmaceuticals Ownership Allocation
The majority of Xenon Pharmaceuticals outstanding shares are owned by institutional investors. These institutions are usually referred to as non-private investors looking to purchase positions in Xenon Pharmaceuticals to benefit from reduced commissions. Consequently, other corporate entities are subject to a different set of regulations than regular investors in Xenon Pharmaceuticals. Please pay attention to any change in the institutional holdings of Xenon Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.Xenon Pharmaceuticals Profitability Analysis
Net Loss for the year was (182.39 M) with loss before overhead, payroll, taxes, and interest of (96.33 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Xenon Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Xenon Pharmaceuticals and how it compares across the competition.
About Xenon Pharmaceuticals Valuation
The stock valuation mechanism determines Xenon Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Xenon Pharmaceuticals. We calculate exposure to Xenon Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Xenon Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -167.5 M | -159.1 M | |
| Pretax Profit Margin | (15.27) | (16.03) | |
| Operating Profit Margin | (15.74) | (16.53) | |
| Net Loss | (15.28) | (16.05) | |
| Gross Profit Margin | (11.74) | (12.33) |
Xenon Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Xenon Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 66.9 M |
Xenon Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Xenon Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Xenon we look at many different elements of the entity such as Xenon's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Xenon Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Xenon Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Xenon Pharmaceuticals' worth.Complementary Tools for Xenon Stock analysis
When running Xenon Pharmaceuticals' price analysis, check to measure Xenon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xenon Pharmaceuticals is operating at the current time. Most of Xenon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xenon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xenon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xenon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |